Angiotech Pharmaceuticals

ANP-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about ANP-T

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
February 1, 2010
What hurts them was they levered up for an acquisition using debt at the wrong time and have never been able to get out from under that cloud of debt and he doesn't think they will.
Show full opinionHide full opinion
What hurts them was they levered up for an acquisition using debt at the wrong time and have never been able to get out from under that cloud of debt and he doesn't think they will.
BUY WEAKNESS
BUY WEAKNESS
June 22, 2009
(Market Call Minute.) A lot of biotech stocks have done well. Would buy on a pullback.
Show full opinionHide full opinion
(Market Call Minute.) A lot of biotech stocks have done well. Would buy on a pullback.
DON'T BUY
DON'T BUY
June 12, 2009
Had 2 approvals, May 27 and June 8. This is on his Watch list but was far more interesting before May 27 so it now holds no interest for him. Might be okay for momentum players.
Show full opinionHide full opinion
Had 2 approvals, May 27 and June 8. This is on his Watch list but was far more interesting before May 27 so it now holds no interest for him. Might be okay for momentum players.
COMMENT
COMMENT
December 11, 2007
The stock has been hurt, but it is more of an issue because of stents. Sales projections are falling off. At this stage, you are probably facing tax loss selling for the rest of the month and then get a January bounce if the company has a decent outlook going forward. Competition has increased in this area.
Show full opinionHide full opinion
The stock has been hurt, but it is more of an issue because of stents. Sales projections are falling off. At this stage, you are probably facing tax loss selling for the rest of the month and then get a January bounce if the company has a decent outlook going forward. Competition has increased in this area.
HOLD
HOLD
July 5, 2007
Have had serious problems with their stents. The whole area is having issues. Excellent management. They have big pipeline and the technology is still excellent.
Show full opinionHide full opinion
Have had serious problems with their stents. The whole area is having issues. Excellent management. They have big pipeline and the technology is still excellent.
SELL
SELL
June 1, 2007
The whole market is going up, and this one is going down. Let someone else own it.
Show full opinionHide full opinion
The whole market is going up, and this one is going down. Let someone else own it.
SELL
SELL
May 1, 2007
A one trick pony with its coated stent. There is lots of controversy on drug coated stents.
Show full opinionHide full opinion
A one trick pony with its coated stent. There is lots of controversy on drug coated stents.
DON'T BUY
DON'T BUY
April 19, 2007
They're very focused on one part of the business, which is stents. There is a lot of competition in this sector. Revenue projections have been dropping.
Show full opinionHide full opinion
They're very focused on one part of the business, which is stents. There is a lot of competition in this sector. Revenue projections have been dropping.
COMMENT
COMMENT
April 17, 2007
Makes drug alluding stents. Its penetration rate in the US was 75% but has dropped to 65%. Will be launching in Japan in the fall. Have a lot of debt on the balance sheet and are in the process of selling assets.
Show full opinionHide full opinion
Makes drug alluding stents. Its penetration rate in the US was 75% but has dropped to 65%. Will be launching in Japan in the fall. Have a lot of debt on the balance sheet and are in the process of selling assets.
BUY
BUY
April 2, 2007
The worst news is already in the stock. At these levels, it's a Buy. Have product pipeline starting to develop. Looking at drug eluding stents in the Japanese market.
Show full opinionHide full opinion
The worst news is already in the stock. At these levels, it's a Buy. Have product pipeline starting to develop. Looking at drug eluding stents in the Japanese market.
DON'T BUY
DON'T BUY
March 28, 2007
A “ one trick pony”. There are now lots of questions to the effectiveness of drug-coated stents.
Show full opinionHide full opinion
A “ one trick pony”. There are now lots of questions to the effectiveness of drug-coated stents.
DON'T BUY
DON'T BUY
March 12, 2007
Not time to buy this one yet. They have the stent problem and the adoption problem. Lowering their earnings forecasts. Potential recovery, but wait for the recovery.
Show full opinionHide full opinion
Not time to buy this one yet. They have the stent problem and the adoption problem. Lowering their earnings forecasts. Potential recovery, but wait for the recovery.
DON'T BUY
DON'T BUY
March 12, 2007
Had a long-term problem with stents. Made a series of acquisitions which all look very interesting. Not sure what the effect of this will be. A raving buy at this price, but does not like buying a stock on the way down.
Show full opinionHide full opinion
Had a long-term problem with stents. Made a series of acquisitions which all look very interesting. Not sure what the effect of this will be. A raving buy at this price, but does not like buying a stock on the way down.
DON'T BUY
DON'T BUY
March 9, 2007
If it breaks $7.35, it is going to go lower. His model price is hugely coming down. In September it was $16 and now it is $10.73, which is a positive differential, but earnings are dropping.
Show full opinionHide full opinion
If it breaks $7.35, it is going to go lower. His model price is hugely coming down. In September it was $16 and now it is $10.73, which is a positive differential, but earnings are dropping.
DON'T BUY
DON'T BUY
February 13, 2007
Guidance for this year was quite poor. Their stent business is not going to be as robust. Company needs to diversify their asset base and have been slow to do that.
Show full opinionHide full opinion
Guidance for this year was quite poor. Their stent business is not going to be as robust. Company needs to diversify their asset base and have been slow to do that.
DON'T BUY
DON'T BUY
February 6, 2007
A great company but not something you should get into at this point. Can't see much upside in the near to intermediate term. Having real problems with clots on their stents. Losing market share. Guidance going forward is coming down. Sold her holdings.
Show full opinionHide full opinion
A great company but not something you should get into at this point. Can't see much upside in the near to intermediate term. Having real problems with clots on their stents. Losing market share. Guidance going forward is coming down. Sold her holdings.
DON'T BUY
DON'T BUY
February 6, 2007
Have been a lot of concerns on their stent products. As a result of this, they acquired a company that would give them revenue and earnings in the event the stents were pulled. Still a lot of risks.
Show full opinionHide full opinion
Have been a lot of concerns on their stent products. As a result of this, they acquired a company that would give them revenue and earnings in the event the stents were pulled. Still a lot of risks.
PAST TOP PICK
PAST TOP PICK
January 22, 2007
(A Top Pick Oct 16/06. Up 9.1%.) Still comfortable with this one. Decent, longer-term story.
Show full opinionHide full opinion
(A Top Pick Oct 16/06. Up 9.1%.) Still comfortable with this one. Decent, longer-term story.
BUY
BUY
December 18, 2006
Got hit with the stent recall for Boston scientific. There are some long-term issues with stents. FDA has decided that the safety issues were not enough to outweigh the benefits. Most of their earnings in the next couple of years will be coming from new products in the pipeline, not stents. Have been very active in acquisitions.
Show full opinionHide full opinion
Got hit with the stent recall for Boston scientific. There are some long-term issues with stents. FDA has decided that the safety issues were not enough to outweigh the benefits. Most of their earnings in the next couple of years will be coming from new products in the pipeline, not stents. Have been very active in acquisitions.
WAIT
WAIT
December 1, 2006
Have been trying to diversify away from their stent business, which is their major source of revenue. There is a fair amount of competition in the sector. Because of the drop in the share price, it could be subject to some tax loss selling.
Show full opinionHide full opinion
Have been trying to diversify away from their stent business, which is their major source of revenue. There is a fair amount of competition in the sector. Because of the drop in the share price, it could be subject to some tax loss selling.
TOP PICK
TOP PICK
November 8, 2006
Stock has come down a long way and valuation looks good. Maintaining their share of the coated stent market. That alone could justify the current price. Acquired another company where they can use the coated technology on other products. Lots of cash. Trading at 12 X earnings.
Show full opinionHide full opinion
Stock has come down a long way and valuation looks good. Maintaining their share of the coated stent market. That alone could justify the current price. Acquired another company where they can use the coated technology on other products. Lots of cash. Trading at 12 X earnings.
PAST TOP PICK
PAST TOP PICK
November 6, 2006
(A Top Pick Aug 21/06. Down 19%.) Had some issues with Boston Scientific (BSX-N) and some problems with their stents. Royalty rate is going down. Still likes the company. They are relying less and less on stents.
Show full opinionHide full opinion
(A Top Pick Aug 21/06. Down 19%.) Had some issues with Boston Scientific (BSX-N) and some problems with their stents. Royalty rate is going down. Still likes the company. They are relying less and less on stents.
DON'T BUY
DON'T BUY
October 18, 2006
Has been under pressure because of competition on their stents. Some controversy as to whether the coated is better or not. Because of this, it is more of a speculation than an investment.
Show full opinionHide full opinion
Has been under pressure because of competition on their stents. Some controversy as to whether the coated is better or not. Because of this, it is more of a speculation than an investment.
TOP PICK
TOP PICK
October 16, 2006
Has been pummelled in the past year. A bit of a contrarian play. Trading around 11 X forward earnings. Made in acquisition that has a great pipeline and, basically, you are paying nothing for that. The stent market is still growing.
Show full opinionHide full opinion
Has been pummelled in the past year. A bit of a contrarian play. Trading around 11 X forward earnings. Made in acquisition that has a great pipeline and, basically, you are paying nothing for that. The stent market is still growing.
BUY
BUY
October 2, 2006
Management is great. It is trading at a low price. Believes it is a buy.
Show full opinionHide full opinion
Management is great. It is trading at a low price. Believes it is a buy.
TOP PICK
TOP PICK
September 27, 2006
Stock recently hit a 52 week low. He is looking at the turnaround here. It has some growth and a good balance sheet. It is in a sector that he likes.
Show full opinionHide full opinion
Stock recently hit a 52 week low. He is looking at the turnaround here. It has some growth and a good balance sheet. It is in a sector that he likes.
BUY
BUY
September 1, 2006
Has come under a bit of pressure which now seems to be easing. Their main business is drug coated stents which they get royalties on. Recently made an acquisition and some of the synergies are now going to start working their way through.
Show full opinionHide full opinion
Has come under a bit of pressure which now seems to be easing. Their main business is drug coated stents which they get royalties on. Recently made an acquisition and some of the synergies are now going to start working their way through.
TOP PICK
TOP PICK
August 31, 2006
Tainted with the stent problem in the US. Incredibly attractive from an earnings point of view. Did some acquisitions that give them 200 new products that they will coat with the same technology they used for their stents.
Show full opinionHide full opinion
Tainted with the stent problem in the US. Incredibly attractive from an earnings point of view. Did some acquisitions that give them 200 new products that they will coat with the same technology they used for their stents.
PAST TOP PICK
PAST TOP PICK
August 4, 2006
(A Top Pick July 4/05. Down 27%.) Below the 50/200-day moving averages. Chart shows a strong downtrend. Had suggested this as a Christmas rally stock.
Show full opinionHide full opinion
(A Top Pick July 4/05. Down 27%.) Below the 50/200-day moving averages. Chart shows a strong downtrend. Had suggested this as a Christmas rally stock.
TOP PICK
TOP PICK
July 31, 2006
Just made a major acquisition. Their coated stent product is still going well. The stock has come under a lot of pressure. They are generating cash and trading at 12 X earnings.
Show full opinionHide full opinion
Just made a major acquisition. Their coated stent product is still going well. The stock has come under a lot of pressure. They are generating cash and trading at 12 X earnings.
Showing 1 to 30 of 140 entries

Angiotech Pharmaceuticals(ANP-T) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Angiotech Pharmaceuticals is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Angiotech Pharmaceuticals(ANP-T) Frequently Asked Questions

What is Angiotech Pharmaceuticals stock symbol?

Angiotech Pharmaceuticals is a OTC stock, trading under the symbol ANP-T on the (). It is usually referred to as or ANP-T

Is Angiotech Pharmaceuticals a buy or a sell?

In the last year, there was no coverage of Angiotech Pharmaceuticals published on Stockchase.

Is Angiotech Pharmaceuticals a good investment or a top pick?

Angiotech Pharmaceuticals was recommended as a Top Pick by John Zechner on 2010-02-01. Read the latest stock experts ratings for Angiotech Pharmaceuticals.

Why is Angiotech Pharmaceuticals stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Angiotech Pharmaceuticals worth watching?

In the last year, there was no coverage of Angiotech Pharmaceuticals published on Stockchase.

What is Angiotech Pharmaceuticals stock price?

On , Angiotech Pharmaceuticals (ANP-T) stock closed at a price of $.